Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026)
Vertex Pharmaceuticals' (VRTX) quarterly Cash from Financing Activities came in at -$538.8 million in Q1 2026, up 20.81% year-on-year from -$446.0 million in Q1 2025, and down 597.93% quarter-over-quarter from -$77.2 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$538.8 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 20.81% year-over-year to -$538.8 million in Q1 2026; TTM through Mar 2026 was -$2.1 billion, a 16.61% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 billion, down 51.27% from the prior year.
- Cash from Financing Activities fell to -$538.8 million in Q1 2026 per VRTX's latest filing, from -$77.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $47.7 million in Q2 2022 and bottomed at -$1.2 billion in Q3 2025.
- The 5-year median for Cash from Financing Activities is -$294.7 million (2023), against an average of -$289.7 million.
- Across the five-year window, Cash from Financing Activities surged 111.96% in 2022 and sank 2172.83% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $40.2 million in 2022, then tumbled by 398.01% to -$119.8 million in 2023, then slumped by 226.63% to -$391.3 million in 2024, then jumped by 80.27% to -$77.2 million in 2025, then sank by 597.93% to -$538.8 million in 2026.
- Per Business Quant, the three latest VRTX Cash from Financing Activities figures stand at -$538.8 million (Q1 2026), -$77.2 million (Q4 2025), and -$1.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 15.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -538.80 Mn |
| Mar 31, 2026 | -538.80 Mn |
| Dec 31, 2025 | -77.20 Mn |
| Dec 31, 2025 | -77.20 Mn |
| Sep 30, 2025 | -1.15 Bn |
| Sep 30, 2025 | -1.15 Bn |
| Jun 30, 2025 | -349.20 Mn |
| Jun 30, 2025 | -349.20 Mn |
| Mar 31, 2025 | -680.40 Mn |
| Mar 31, 2025 | -680.40 Mn |
| Dec 31, 2024 | -391.30 Mn |
| Dec 31, 2024 | -391.30 Mn |
| Sep 30, 2024 | -387.50 Mn |
| Sep 30, 2024 | -387.50 Mn |
| Jun 30, 2024 | -358.60 Mn |
| Jun 30, 2024 | -358.60 Mn |
| Mar 31, 2024 | -357.50 Mn |
| Mar 31, 2024 | -357.50 Mn |
| Dec 31, 2023 | -119.80 Mn |
| Dec 31, 2023 | -119.80 Mn |